Ampio Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Ampio Pharmaceuticals.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	21.3%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Ampio Pharmaceuticals no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

DB:APH - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2023	N/A	-9	-11	-11	N/A
6/30/2023	N/A	-14	-16	-16	N/A
3/31/2023	N/A	-15	-18	-18	N/A
12/31/2022	N/A	-16	-21	-21	N/A
9/30/2022	N/A	-20	-21	-21	N/A
6/30/2022	N/A	-18	-19	-19	N/A
3/31/2022	N/A	-19	-15	-15	N/A
12/31/2021	N/A	-17	-14	-14	N/A
9/30/2021	N/A	-15	-13	-13	N/A
6/30/2021	N/A	-15	-12	-12	N/A
3/31/2021	N/A	-14	-14	-14	N/A
12/31/2020	N/A	-16	-15	-15	N/A
9/30/2020	N/A	-12	-17	-17	N/A
6/30/2020	N/A	-16	-19	-19	N/A
3/31/2020	N/A	-13	-18	-17	N/A
12/31/2019	N/A	-14	-15	-15	N/A
9/30/2019	N/A	-11	-13	-13	N/A
6/30/2019	N/A	2	-12	-11	N/A
3/31/2019	N/A	6	-11	-11	N/A
12/31/2018	N/A	34	-13	-12	N/A
9/30/2018	N/A	-11	-13	-12	N/A
6/30/2018	N/A	-21	-13	-12	N/A
3/31/2018	N/A	-28	-13	-12	N/A
12/31/2017	N/A	-52	-11	-11	N/A
9/30/2017	N/A	-12	-11	-11	N/A
6/30/2017	N/A	-12	N/A	-11	N/A
3/31/2017	N/A	-14	N/A	-12	N/A
12/31/2016	N/A	-19	N/A	-15	N/A
9/30/2016	N/A	-22	N/A	-20	N/A
6/30/2016	N/A	-23	N/A	-24	N/A
3/31/2016	N/A	-24	N/A	-24	N/A
12/31/2015	N/A	-22	N/A	-26	N/A
9/30/2015	0	-26	N/A	-24	N/A
6/30/2015	0	-30	N/A	-25	N/A
3/31/2015	0	-33	N/A	-29	N/A
12/31/2014	N/A	-30	N/A	-31	N/A
9/30/2014	0	-36	N/A	-30	N/A
6/30/2014	0	-32	N/A	-29	N/A
3/31/2014	0	-30	N/A	-24	N/A
12/31/2013	0	-24	N/A	-19	N/A
9/30/2013	0	-20	N/A	-17	N/A
6/30/2013	0	-17	N/A	-13	N/A
3/31/2013	0	-13	N/A	-10	N/A
12/31/2012	0	-12	N/A	-10	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de APH es superior a la tasa de ahorro (0.5%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de APH crezcan más rápidamente que el mercado German

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de APH crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de APH crezcan más rápidamente que el mercado de German.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de APH crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de APH se prevé que sea elevada dentro de 3 años.

Ampio Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Levi & Korsinsky Notifies Ampio Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NYSE to Commence Delisting Procedure for Ampio Pharmaceuticals' Common Stock

Glancy Prongay & Murray LLP Files A Class Action Lawsuit Against Ampio Pharmaceuticals, Inc

Robbins LLP Files A Securities Fraud Lawsuit Against Ampio Pharmaceuticals, Inc

Ampio Pharmaceuticals, Inc., Annual General Meeting, Aug 10, 2022

Ampio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Less than half of directors are independent

Ampio Pharmaceuticals, Inc. Announces Executive Changes

Ampio Provides Regulatory Update

Ampio Pharmaceuticals Releases Positive Phase 3 Data Analysis for Ampion Targeting Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals Appoints Elizabeth Varki Jobes as Member of the Board and as Member of the Nominating and Corporate Governance Committee of the Board

Less than half of directors are independent

Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India

Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory Distress

Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program

Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India

Ampio Pharmaceuticals, Inc. Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial

Ampio Pharmaceuticals, Inc. Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19

Ampio Pharmaceuticals Reveals Early Positive Results for Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals, Inc. Brings New Hospitals Online in Trial for Inhalation Treatment of COVID-19 with Ampion

Ampio Pharmaceuticals, Inc. Announces Early Positive Data in Phase 1 Trial of Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals Provides Update on Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19

Ampio Provides Update on Clinical Trials for Ampion™ Treatment of Covid-19 Patients

Ampio Pharmaceuticals, Inc. Receives Feedback from the FDA on Ampio’s Proposed Modifications to the Special Protocol Asssessment for Ampion Treatment of Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals, Inc. Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion

Ampio Pharmaceuticals, Inc. Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug, Ampion

New 90-day high: €0.98

Ampio Pharmaceuticals, Inc. Announces the AP-014 Phase I Inhaled Ampion™ Clinical Study In COVID-19 Patients

Ampio Pharmaceuticals, Inc. Announces its Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Begins Phase 1 Clinical Trial of Inhaled Ampion for Covid-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation

Ampio Pharmaceuticals, Inc. Announces the Receipt of an Investigational New Drug from the U.S. Food and Drug Administration

New 90-day high - €0.69

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento